New brain cancer drug trial aims to slow deadly tumor growth
NCT ID NCT02981940
Summary
This study is testing an experimental drug called abemaciclib for adults with glioblastoma, an aggressive brain cancer that has returned after initial treatment. The main goals are to see if the drug reaches the brain tumor effectively and if it can help slow the cancer's progression. Researchers are enrolling 45 participants to evaluate safety and how well the treatment works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10021, United States
-
UT, M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Francisco
San Francisco, California, 94143-0372, United States
Conditions
Explore the condition pages connected to this study.